NTRR Joint Venture Offers New Antimicrobial Solutions to Embattled Colorado Cannabis Growers

TAMPA, Fla.--()--As testing continues in Colorado on horticultural products marketed by Neutra Corp. (OTCBB:NTRR) and its joint venture partner, Surface to Air Solutions (S2O2), the companies are already receiving a great deal of interest from cannabis growers in the state. In response, each Friday in April, S2O2 will conduct educational information sessions on its suite of antimicrobial alternatives to pesticides, hosted by respected cultivation organization Denver Consulting Group.

Last month, S2O2 signed letter of intent with Denver Consulting Group to test and demonstrate the efficacy of its horticultural product suite at the company’s indoor growing operations in the state.

“These open information sessions are the perfect way to spread the word on these products before the official testing cycle is complete,” said NTRR CEO Chris Brown. “We have been blown away by the response to these products’ potential for the cannabis industry. Growers are ready for real, effective alternatives to pesticides for indoor cultivation.”

NTRR formed the joint venture with S2O2 last year to market novel and ideal solutions to growers that are concerned about contamination of their crops by microbes, molds, fungus and other pests. The companies are marketing a suite of products that includes an antimicrobial surface treatment, a nutritional plant tonic and an air-scrubbing hydroxyl generator capable of keeping growing facilities sterile without the use of harsh chemicals.

With interest rising and the results of its lab testing to be completed once the 90-day testing period is complete, NTRR and its joint venture partner are expecting a highly successful commercial launch for the products, which are currently being tested in Colorado, California and Canada.

About Neutra Corp.

Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (OTCBB: GWPRF), INSYS Therapeutics, Inc. (NASDAQ: INSY) and ENDEXX Corp. (OTCBB: EDXC), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contacts

Neutra Corp.
Chris Brown, 813-367-2041
President and CEO
info@neutracorp.com

Release Summary

NTRR Joint Venture Offers New Antimicrobial Solutions to Embattled Colorado Cannabis Growers

Contacts

Neutra Corp.
Chris Brown, 813-367-2041
President and CEO
info@neutracorp.com